Oscient reiterated at market outperform by JMP

JMP Security analyst Adam Cutler reiterated Oscient Pharmaceuticals Corp. at market outperform as it continues to track weekly Factive and Testim prescription volumes using NDC Health data. For the week ended May 12, total Factive prescriptions were 5,730 (5,587 new, or 0.91% of weekly prescriptions for the quinolone class of antibiotics. This compares with 5,677 total prescriptions (5,481 new) in the previous week, or 0.90% of weekly prescriptions from the quinolone class. Through May 12, 33,556 Factive prescriptions have been written for the second quarter generating about $3 million in revenue. Testim scripts for the week ended May 12 totaled 5,826, up from 5,803 the previous week. Shares of the Waltham, Mass., biopharmaceutical company were up 10 cents, or 8.00%, at $1.35 on volume of 683,293 shares versus the three-month running average of 480,756 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.